Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Payables (2021 - 2025)

Universe Pharmaceuticals (UPC) has disclosed Payables for 5 consecutive years, with $7.4 billion as the latest value for Q3 2025.

  • Quarterly Payables rose 19.37% to $7.4 billion in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $7.4 billion through Sep 2025, up 19.37% year-over-year, with the annual reading at $7.4 billion for FY2025, 19.37% up from the prior year.
  • Payables hit $7.4 billion in Q3 2025 for Universe Pharmaceuticals, up from $6.2 billion in the prior quarter.
  • In the past five years, Payables ranged from a high of $7.4 billion in Q3 2025 to a low of $7.0 million in Q3 2022.
  • Historically, Payables has averaged $2.7 billion across 5 years, with a median of $10.1 million in 2023.
  • Biggest five-year swings in Payables: decreased 27.3% in 2022 and later surged 61577.77% in 2024.
  • Year by year, Payables stood at $9.6 million in 2021, then fell by 27.3% to $7.0 million in 2022, then surged by 43.59% to $10.1 million in 2023, then soared by 61577.77% to $6.2 billion in 2024, then increased by 19.37% to $7.4 billion in 2025.
  • Business Quant data shows Payables for UPC at $7.4 billion in Q3 2025, $6.2 billion in Q3 2024, and $10.1 million in Q3 2023.